FDA Approves Combination Sumatriptan/Naproxen Sodium for Acute Treatment of MigraineNEW YORK -- April 17, 2008 -- The US Food and Drug Administration (FDA) has approved a combination pill, sumatriptan/naproxen sodium (Treximet) for the acute treatment of migraine attacks with or without aura in adults. This is the first and only migraine treatment that combines 2 therapies in 1 tablet -- a triptan and an anti-inflammatory pain reliever -- thereby targeting multiple mechanisms of migraine. The combination pill contains sumatriptan 85 mg and naproxen sodium 500 mg.In clinical trials, a significantly greater percentage of patients achieved migraine pain relief at 2 hours with the sumatriptan/naproxen combination compared with sumatriptan 85 mg or naproxen sodium 500 mg alone. In addition, the combination pill provided more patients with sustained migraine pain relief from 2 to 24 hours compared with the individual components. The new pill will be available in mid May, 2008.